Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2018 Publisher: Piramal Critical Care Limited, Suite 4, Ground Floor, Heathrow Boulevard East Wing, 280 Bath Road, West Drayton, UB7 0DQ, United Kingdom, Tel: 00441670562400
Hypnomidate 2 mg/ml Injection.
| Pharmaceutical Form |
|---|
|
Solution for injection. |
Each ml of Hypnomidate contains etomidate 2 mg.
| Active Ingredient | Description | |
|---|---|---|
| Etomidate |
Etomidate is an imidazole derivative with short-acting sedative, hypnotic, and general anesthetic properties. Etomidate appears to have gamma-aminobutyric acid (GABA) like effects, mediated through GABA-A receptor. The action enhances the inhibitory effect of GABA on the central nervous system by causing chloride channel opening events which leads to membrane hyperpolarization. |
| List of Excipients |
|---|
|
Propylene glycol * for occasional pH adjustment only |
Colourless glass ampoule, Ph.Eur. Type I, containing 10 ml Hypnomidate, in packs of 5 and 10 ampoules.
Not all pack sizes may be marketed.
Piramal Critical Care Limited, Suite 4, Ground Floor, Heathrow Boulevard – East Wing, 280 Bath Road, West Drayton, UB7 0DQ, United Kingdom, Tel: 00441670562400
PL 37071/0006
27 October 1978/20 March 2004
| Drug | Countries | |
|---|---|---|
| HYPNOMIDATE | Austria, Brazil, Estonia, Spain, France, Croatia, Malta, Netherlands, Poland, Tunisia, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
